Jump to content
Script NAD

A cinematic reading of the NAD+ literature — the coenzyme drawn in a single cold light: a cellular brightness that dims with age, and the precursor research that tries to raise it back.

SCENE / THE PUBLISHER

About Script NAD

A cold-light reading of the NAD+ literature — the studies lit one scene at a time, and nothing else behind the frame.

Read the researchContact

What this site is

Script NAD reads the NAD+ literature the way a cutting room reads footage — scene by scene, each study on NAD+ and its precursors (NMN, NR, nicotinamide) lit, logged, and reported for what it measured, in plain language. It is a reading, not a service. No clinic stands behind the frame, no pharmacy, no telehealth desk; the site makes nothing and sells nothing. It writes no prescription, hands out no diagnosis or dosing, and no clinician sits in the room. What it keeps is a plain, cited account of the record — the figures, the trial names, the identifiers, logged to source.

What 'Script NAD' means

The name reads "script" as a screenplay — a shot list of the NAD+ literature, each study lit and indexed like a scene — not as a prescription pad. The cinematic framing is a method of reading, and it describes nothing the site does for a visitor. We write no prescriptions, run no telehealth pathway, and imply no “approved NAD+ drug” waiting to be prescribed: NAD+ is not FDA-approved for any disease, and most oral products are precursors sold as dietary supplements. The light in the design falls on the data; there is no clinic behind it.

How we handle the evidence

We hold a few lines firmly. Every quantitative claim on the site cites a specific study, listed on the references and citations page. We keep the distinction between NAD+ and its precursors exact — an oral NMN or NR trial is never described as "taking NAD+." We separate human findings from rodent findings explicitly, because the strongest anti-aging data remain in animals while human outcome data stay limited. And we mark the genuine cautions plainly: the compounded, unapproved status of IV NAD+, the FDA Class I endotoxin recall of a compounded injection, and the unsettled marketplace dispute over NMN's supplement status. We describe; we do not recommend.

What we are not

We are not a healthcare provider, a pharmacy, a compounding facility, or a supplement vendor. We do not offer treatment, consultation, prescriptions, or dosing instructions, and no content here should be read as any of those. NAD+ research is active and evolving; our role is to track the published record accurately and present it for general readers and researchers, not to advise anyone on what to do.